ArticleEuropean journal of public health2024
Understanding the high-risk human papillomavirus prevalence and associated factors in the European country with a high incidence of cervical cancer.
Article in European journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Epidemiological Profile of High-Risk HPV in Cervical Samples for Liquid-Based Cytology: Insights from Screening and Symptomatic Cohorts.Microorganisms · 2026Article
- Beyond HPV in Eastern Europe: Genotype Distribution, Molecular Biomarkers, Vaginal Microbiome, and Implications for Cervical Cancer Prevention.Life (Basel, Switzerland) · 2026Review
- Article
- Population-based self-sampling under primary care conditions - a possible approach for cervical cancer screening in Indonesia (IndoCerCa study).Reproductive health · 2026Article
- Prevalence of high-risk human papillomavirus genotypes and associated HIV co-infection in Cameroon: a systematic review and meta-analysis.Infectious agents and cancer · 2026Article
- Women's compliance with cervical cancer screening recommendations and associated barriers to participation: A cross-sectional analysis.PloS one · 2026Article
- Factors associated with women's choice for mode of cervical sampling in future cervical cancer screening.PloS one · 2026Article
- Online Conference "Chronic Viral Infections and Cancer, Openings for Vaccines and Cure" VIRCAN2024, Monitoring the Progress.Vaccines · 2025Article
- Cervical Cancer in the Era of HPV: Translating Molecular Mechanisms into Preventive Public Health Action.International journal of molecular sciences · 2025Review
- Genotype-Specific Distribution of High-Risk Human Papillomavirus (HPV) and Microbial Co-Detections in HPV-Positive Women from Southern Croatia.Biomedicines · 2025Article
- Screening for Cervical Cancer and Early Treatment (SCCET) Project-The Programmatic Data of Romanian Experience in Primary Screening for High-Risk HPV DNA.Diagnostics (Basel, Switzerland) · 2025Article
- Human papillomavirus infection and screening strategies.World journal of clinical oncology · 2025Review
- Prevalence and Genotype Distribution of High-Risk HPV Genotypes Among Women in Greece: A Retrospective Analysis of 3500 Women.Cancers · 2025Article
- Cervical cancer screening: Impact of collection technique on human papillomavirus detection and genotyping.Preventive medicine reports · 2025Article
- Integrated HPV Testing, TCT, and Colposcopic VIA/VILI Improves Detection Rate for HSIL and Cervical Cancer: A Retrospective Cohort in China.International journal of women's health · 2025Article
- Persistently high prevalence of HPV16 and rising prevalence of non-16/18 HR-HPV genotypes in cervical precancer and cancer in Latvia in 2016-2024 shape the severity of cervical disease.Frontiers in oncology · 2025Article
- Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening.Frontiers in oncology · 2025Article
- Prevalence of Human Papillomavirus Subtypes and Related Cytology in Estonian Cervical Cancer Screening Population in 2021.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHigh-risk human papillomavirus (HR-HPV) is a known cause of cervical cancer (CC). Latvia has a high incidence of CC compared with the average incidence in the European Union. This study aims to fill the data gap on the HR-HPV burden in Latvia, providing information on its prevalence and associated factors.
methodsThe cross-sectional study was conducted from February 2021 to April 2022. Participants 25-70 years old visiting a general practitioner (general population) or those referred to a colposcopy clinic with changes in their cervical cytology (colposcopy population) collected vaginal self-sample and completed a paper-based questionnaire. Samples were analyzed with Cobas 6800 System (Roche) for HPV16, HPV18 and other HR-HPV (HPV31/33/35/39/45/51/52/56/58/59/66/68). Descriptive statistics for categorical variables were performed. The Chi-square test was used to determine for the statistical significance of differences in the proportions of the dependent variable between subgroups of the independent variable. Univariate and multivariate binary logistic regression were used to identify factors associated with positive HR-HPV status. Results were considered statistically significant at P < 0.05.
resultsA total of 1274 participants provided a valid sample. The prevalence of any HR-HPV infection was 66.8% in the colposcopy group and 11.0% in the general population. Factors associated with positive HR-HPV status were marital status single/divorced/widowed (vs. married/cohabiting) [adjusted OR (aOR) 2.6; P = 0.003], higher number of lifetime sex partners [aOR 5.1 (P < 0.001) and 4.0 (P = 0.001)] for six or more and three to five partners in the general population; in the colposcopy group, the statistical significance remained only for Latvian ethnicity (vs. other) (aOR 1.8; P = 0.008) and current smoking (vs. never) (aOR 1.9; P = 0.01).
conclusionWe documented a comparison to European Union HR-HPV infection burden in Latvia. Any HR-HPV positivity was significantly associated with sexual and other health behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.